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Update on glasdegib in acute myeloid leukemia – broadening 
horizons of Hedgehog pathway inhibitors
Numerous new emerging therapies, including oral tar-
geted chemotherapies, have recently entered the thera-
peutic arsenal against acute myeloid leukemia (AML). 
The significant shift toward the use of these novel thera-
peutics, administered either alone or in combination 
with intensive or low-intensity chemotherapy, changes 
the prospects for the control of this disease, especially 
for elderly patients. Glasdegib, an oral Hedgehog path-
way inhibitor, showed satisfactory response rates asso-
ciated with moderate toxicity and less early mortality 
than standard induction regimens in this population. It 
was approved in November 2018 by the FDA and in June 
2020 by the EMA for use in combination with low-dose 
cytarabine as a treatment of newly-diagnosed AML in 
patients aged ≥ 75 and/or unfit for intensive induction 
chemotherapy. The current paper proposes an exten-
sive, up-to-date review of the preclinical and clinical 
development of glasdegib. Elements of its routine clini-
cal use and the landscape of ongoing clinical trials are 
also stated.
Keywords: glasdegib, PF-04449913, PF-913, acute myeloid 
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INTRODUCTION
The hedgehog (HH) intracellular signaling pathway, first described in Drosophila in 1980 
(1), has a significant role in normal embryonic development and adult stem cell persistence 
(2–4). The physiological HH pathway (Fig. 1) is dependent upon 3 known human ligands, 
triggering a concentration- and gradient-dependent response (3). They are lipid-modified 
secreted proteins named Sonic HH (SHH), Indian HH (IHH) and Desert HH (DHH) (4). 
These ligands can bind to negative-regulator receptors named Patched (PTCH1 and 
PTCH2, 12-pass transmembrane proteins) (5), resulting in the derepression of the G-pro-
tein-like transducer Smoothened (SMO, a 7-pass transmembrane protein) (6). Intracellular 
glioma zinc finger transcription factors (GLI1, GLI2 and GLI3) are then activated by SMO and 
promote the expression of several HH-pathway-related genes, such as BCL2, cMYC and 
SNAIL (7–9). Overall, expression levels of GLI1 are well correlated with the HH pathway 
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activity, although the expression of this factor can also be enhanced by several SMO-inde-
pendent mechanisms (10).
HH pathway and GLI abnormal signaling are associated with dysregulation of cell 
regeneration and redifferentiation. Thus, these modifications can be found in several types 
of cancer (11). Among these diseases, the role of deviant HH signaling in hematological 
cancers has been particularly emphasized, especially in myeloid malignancies (12–14). In 
acute myeloid leukemia (AML), HH pathway overexpression was objectified in myeloblas-
tic cells (15, 16) and was associated with cell survival, chemoresistance and radiotherapy 
resistance (17–21). Therefore, the HH pathway and, more specifically, the SMO protein 
appeared as a promising pharmacological target, which may be inhibited by small mole-
cules. Numerous derivatives have been developed as SMO inhibitors (22), the most widely 
used in oncology being vismodegib, sonidegib and glasdegib. Although preclinical studies 
have shown significant efficacy of vismodegib and sonidegib in hematological cancer 
 models (21, 23, 24), these two drugs had little clinical evaluation in patients with leukemic 
pathologies (25). On the other hand, glasdegib has been studied more intensively as a  potential 
treatment in acute myeloid leukemia. Following the positive results of phase II clinical 
trials (26), glasdegib received its first approval in the USA on 21 November 2018 for its use 
in the combination with low dose cytarabine (LDAC) in newly-diagnosed AML patients ≥ 
75 years or with comorbidities that contraindicate the use of intensive induction chemo-
therapy (IC) (27, 28). This approval was almost simultaneous with the authorization of 
ivosidenib and gilteritinib in the treatment of AML and came one year after the approval 
of midostaurin, enasidenib and gemtuzumab ozogamycin as therapeutic alternatives in 
Fig. 1. Simplified physiological HH pathway signaling.
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AML. In this context, the way in which these molecules should be used and their respec-
tive advantages have given rise to much debate (29–31). The purpose of this review is to 
provide a comprehensive update on glasdegib as an active ingredient, from its discovery 
to the practical considerations of its therapeutic use in AML, with particular emphasis on 
its clinical evaluation.
PHARMACOLOGY AND PRECLINICAL STUDIES
Glasdegib, formerly PF-04449913 or PF-913, was initially identified by Munchhof et al. 
among a small series of benzimidazole-based Smoothened inhibitors (32). It resulted from 
the optimization of a former hit molecule with suboptimal physicochemical properties 
(33). In addition to preserved in vitro efficacy (IC50 in Gli-luciferase reporter assay is 5 nmol 
L–1), glasdegib also displayed good in vitro microsomal stability, 9 % free fraction in plasma 
and promising physicochemical properties (Table I). According to in vivo pharmaco kinetic 
studies in rats and dogs, glasdegib was predicted to have good PK properties in humans 
(1.03 mL min–1 kg–1 plasma clearance, 2.7 L kg–1 volume of distribution, 30 h half-life and 
55 % oral bioavailability) along with excellent potency.
In a preclinical study involving a PTCH1+/-p53 mouse model of medulloblastoma and 
human patient-derived xenograft models, glasdegib displayed potent dose-dependent 
inhi bition of the HH pathway, resulting in stable tumor regression (34). Glasdegib-treated 
medulloblastoma allografts had reduced levels of Gli1 gene expression and downregula-
tion of genes linked to the Hh signaling pathway. This GLI1 downregulation is consistent 










Molar mass (g mol–1) 374
Measured log D 2.48
Gli-luciferase reporter in C3H10T1/2 IC50 (nmol L–1) 5
Human microsomes CLi (mL min–1 kg–1) 6.3
Human plasma protein binding (% free) 9.1
Ames test Negative
Micronucleus assay Negative
In vivo pharmacokinetics In rat In dog
CL (mL min–1 kg–1) 31 3.9




T1/2 (h) 1.4 2.9
F (%) 33 68
IC50 – half-maximal inhibitory concentration, CLi – intrinsic clearance, CL – plasma clearance, Vss – steady state 
volume of distribution; T1/2 – plasma terminal half-life; F – oral bioavailability.
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with the results subsequently obtained in clinical trials (35, 36), however, glasdegib’s mode 
of action remained unclear at the cellular and molecular level. Thus, the pharmacology of 
this drug was studied on a Drosophila model that confirmed its SMO inhibition activity 
(37). As a consequence, blood cell homeostasis was disrupted in a way that could cause, in 
humans, leukemic stem cells (LSC) to exit from the bone marrow. These LSC, known to 
persist beyond conventional treatment cessation and to result in a relapse in myeloid 
 diseases such as AML (38, 39), could enter the bloodstream and become sensitive to thera-
peutic agents (12, 40). Similar results were obtained in vitro, also presenting bone marrow 
stromal cells as a possible target of Smo inhibitors to decrease the quiescent LSC popula-
tion (41). In an AML xenograft mouse model, glasdegib showed synergistic action with 
LDAC in inhibiting tumor growth and limiting the percentage of CD45+/CD33+ blasts in 
the bone marrow (41). As previously proposed, glasdegib-treated AML cells showed 
 increased sensitivity to chemotherapeutic agents such as cytarabine, highlighting the  benefit 
of glasdegib plus chemotherapy association. Effects of glasdegib on LSC quiescence, 
 survival and self-renewal were also investigated on mice intrahepatically transplanted 
with blast crisis chronic myeloid leukemia (CML) LSCs (42). Mice were treated for 14 days 
by daily oral gavage with dasatinib alone (50 mg kg–1) or glasdegib (100 mg kg–1) with or 
without dasatinib (50 mg kg–1). Combination treatment with glasdegib and dasatinib 
 revealed a significant decrease in LSC hepatic engraftment compared with glasdegib or 
dasatinib alone. Cell cycle analysis also demonstrated a reduction in quiescent human 
leukemic cells in the peripheral blood and in the bone marrow following SMO inhibitor 
treatment (43). Like in the previous study, Chaudhry et al. documented the benefits of  using 
glasdegib in an association, emphasizing the key role of Gli3r for the therapeutic effect of 
SMO antagonists in AML (44). They demonstrated that GLI3 gene expression was epigene-
tically silenced in most AML, causing glasdegib ineffectiveness. However, treatment with 
hypomethylating agents (HMA), such as decitabine, restored GLI3 expression and therefore 
glasdegib efficacy. Similar results were also obtained concerning GLI2 expression (45, 46). 
Some clinical trials’ protocols presented subsequently are based on this mechanistic  rationale 
for combining chemotherapeutic agents and SMO antagonists in AML.
CLINICAL EVALUATION
Phase I
After a first-in-patient preliminary evaluation (47), Martinelli et al. reported an open-
label, multi-center phase Ia dose-escalation study (NCT00953758) to assess first-cycle dose- 
-limiting toxicities (DLTs) and the recommended phase II dose (RP2D) of glasdegib (35, 47). 
Forty-seven patients have been enrolled at doses from 5 mg to 600 mg orally once daily, for 
1 to 537 days. Patients had refractory, resistant, or intolerant selected hematologic malig-
nancies such as AML (n = 28), CML (n = 5), myelodysplastic syndrome (MDS, n = 6), myelo-
fibrosis (MF, n = 7) or chronic myelomonocytic leukemia (CMML, n = 1). One of the AML 
patients achieved complete remission with incomplete blood count recovery (CRi, bone 
marrow blast count decreased from 92 to 1 %), seven AML patients had a stable bone mar-
row blast count, one patient with low-risk MDS achieved a significant reduction in spleen 
size and a hematologic improvement in platelets (from 98.5 to 369 × 109 L–1) and neutro-
phils, five patients with MF attained stable disease, and one patient with T3151 lymphoid 
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blast crisis CML achieved a major cytogenetic response with loss of the T3151 mutation. 
The gene expression profile analysis of bone marrow LSC progenitors evidenced that glas-
degib triggered HH pathway genes (Gas1, Kif 27) up-regulation (48) and chemoresistance 
genes (ABCA2, Bcl2) downregulation (49). Overall, glasdegib showed preliminary clinical 
activity in nearly half of the patients in the study. Four patients discontinued the study due 
to a treatment-related adverse event (TRAE): hemorrhagic gastritis (10 mg group), decreased 
appetite (40 mg group), peripheral oedema (400 mg) and decreased weight (600 mg group). 
The majority of AEs were of G1/2 severity, including dysguesia (28 %), decreased appetite 
(19 %), alopecia (15 %), diarrhea (13 %), nausea (13%) and vomiting (11 %). Glasdegib PK 
data indicated a dose-proportional profile, with a Tmax of 1–2 hours, a mean half-life of 
about 24 hours and a large volume of distribution (250–480 L). Steady-state was achieved 
in 8 days and the median accumulation ratio ranged from 1.3 to 2.9. Based on the safety, 
tolerability, pharmacodynamic analysis and preliminary clinical activity reported, the 
RP2D for treatment with glasdegib was established to be 200 mg or lower once daily.
In view on the encouraging results of this first study, Minami et al. reported the partial 
results of an open-label, multicenter phase I trial (NCT02038777) of glasdegib in 13 Japanese 
patients with AML (n = 7), MDS (n = 4), CMML (n = 1) or MF (n = 1) (50). Glasdegib was admi-
ni stered orally once a day at 25 mg, 50 mg or 100 mg for 36 to 332 days and didn’t cause any 
DLT, although treatment was permanently discontinued in 4 patients due to AE (3 at 50 mg 
and 1 at 100 mg). Observed AEs were very consistent with those reported by Martinelli et al. 
(35). Preliminary clinical activity data showed that 1 AML patient achieved morphological 
complete remission (CR) in the 100 mg group and 4 AML patients (1 each in the 20 mg and 
50 group, 2 in the 100 mg group) achieved stable disease. One MDS patient in the 100 mg 
group achieved marrow complete remission and 2 MDS patients (1 each in the 25 mg and 
100 mg group) achieved stable disease. Glasdegib PK parameters were comparable to those 
previously reported (dose-proportional kinetics, Tmax = 2–4 h, T1/2 = 20.7 ± 7.7 h).
The first combination of glasdegib with standard chemotherapy in patients was 
 reported by Savona et al. (51). In an open-label, multicenter, dose-escalation, phase Ib study 
(BRIGHT AML 1003, NCT01546038), glasdegib 100 mg or 200 mg was administered orally, 
once a day during 2–567 days, in combination with LDAC (n = 23, arm A), decitabine (n = 7, 
arm B) or cytarabine/daunorubicin (n = 22, arm C). Most patients had a diagnosis of AML 
(87 %, 71 % and 91 % of patients in arm A, B and C, respectively); others were MDS patients. 
In this population, a clinically beneficial response was observed in 2 (10 %), 3 (60 %) and 
12 (60 %) patients in arms A, B and C, respectively. However, these response rates were not 
significantly different than those expected with standard treatment alone. Overall sur-
vival (OS) was 4.4, 11.5 and 34.7 months in arm A, B and C, respectively. Analysis of gene 
mutation profiles in responders and non-responders did not indicate that clinical response 
could be predicted by any particular mutation profile. In the same way, minimal or incon-
sistent changes were evident in circulating cytokines in these patients. No DLTs were 
 observed in arm A and arm B, but 1 DLT (grade 4 neuropathy) occurred in arm C. The most 
common non-hematologic TRAEs were mostly graded 1 and 2 in all arms. Muscle spasms, 
considered the most frequent TRAE, were observed in 49 to 76 % of patients. Based on the 
tolerability, efficacy and PK profile of glasdegib in combination with chemotherapy regi-
mens, the authors selected an RP2D of 100 mg daily as a basis for further evaluations in 
these patient populations.
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To compensate for the low number of patients with MDS in this study, another open-
label phase Ib clinical trial aimed to enroll more MDS patients. In this BRIGHT MDS & 
AML 1012 study (NCT02367456), early trends suggested an acceptable safety profile for the 
combination of glasdegib 100 mg daily with azacytidine (AZA) 75 mg m–2 day 1–7 every 
25 days (52, 53). The number of CR (3 for 12 patients in 2015, 5 for 30 patients in 2019)  appeared 
favorable in comparison with AZA alone. Analysis of early hematopoietic recovery and 
transfusion independence showed that early platelet recovery was correlated with 
 response to treatment (54). Among patients with MDS and AML (both n = 30 in 2019), 
 respectively, 54 % (7/13) and 64 % (9/14) of evaluable transfusion-dependent patients at 
baseline became transfusion-independent after an average treatment duration of 5 months. 
In addition to this early marrow recovery, the glasdegib + ASA combination did not seem 
to impact negatively the health-related quality of life of patients (55). Definitive conclu-
sions of this study are still pending.
Gerds et al. reported a single-arm, lead-in cohort, open-label phase Ib/II trial 
(NCT02226172) of glasdegib in patients with primary or secondary MF previously treated 
with at least 1 JAK inhibitor (56). Twenty-one patients received 100 mg glasdegib orally for 
up to 24 weeks. Approximately 40 % of patients achieved > 20 to 30 % reduction in symp-
toms, suggesting that glasdegib could have a significant benefit in improving MF-related 
clinical manifestations. However, mean spleen volume measured by MRI or CT at weak 24 
suggested this treatment may not sustainably decrease spleen volume in this patient popu-
lation (mean percentage change from baseline in spleen volume was +10.92 %; 3 patients 
with stabilization or reduction in spleen size). All 21 patients experienced one or more 
TRAE, causing permanent treatment discontinuation for 12 (57.1 %) patients, mostly due 
to muscle spasms (n = 6) and dysgeusia (n = 3). Although the frequencies of TRAEs in this 
population were higher than those reported in previous studies, the toxicity profile of 
glasdegib was considered manageable. The authors proposed to consider alternative dos-
ing schedules as a strategy to increase tolerability of glasdegib in similar populations.
Glasdegib was also evaluated in 23 patients with various advanced solid tumors, 
through an open-label, multicenter, phase I study (NCT01286467, 36). Eight patients 
achieved stable disease and glasdegib was well tolerated at doses of 80–320 mg, once daily. 
TRAEs and PK parameters were consistent with previous statements.
Phase II
After the phase I studies of glasdegib in myeloid malignancies, this SMO inhibitor 
was evaluated in combination within larger patient cohorts. In an open-label, phase II, 
multicenter trial (BRIGHT AML 1003 “intensive arm”, NCT01546038), previously untreated 
patients with AML (n = 66) or high-risk MDS (n = 5) received glasdegib 100 mg orally once 
daily in 28-days cycles (range 10–501 days), with intravenous daunorubicin 60 mg m–2 on 
days 1–3 and continuous intravenous cytarabine (100 mg/1.73 m²) on days 1–7 of every 
cycle (57). Of the 69 patients included in the full analysis set, 46.6 % (80 % CI 38.7–54.1) 
achieved CR, among which 40.0 % (31.9–48.1) of patients aged ≥ 55 years and 88.9 % (75.5–
100.0) of patients aged < 55 years. These values are within the range of those reported for 
other AML therapies, or even slightly better (58–60). The median duration of CR was 94 
(range 1–480) days in all patients and 103 (1–480) and 50 (1–268) days in patients aged ≥ 55 
years and < 55 years, respectively. These results have certainly contributed to the positioning 
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of glasdegib as a therapeutic alternative in AML for elderly populations (61). Overall, 35 
(54.7 %) AML patients and 2 (40 %) MDS patients achieved CR/CRi. The combination of 
glasdegib with cytarabine and daunorubicin caused mostly low-grade diarrhea and 
 nausea, however, more than 80 % of patients experienced grade 3 adverse events (AEs). 
Across all patients, 14 (20.3 %) and 25 (36.2 %) patients permanently or temporarily, respec-
tively, discontinued study treatments (glasdegib and/or cytarabine/daunorubicin) due to 
AEs. Five (7.2 %) patients had dose reductions due to AEs. Expression levels of several 
genes were investigated and showed that FLT3 mutations and high PTCH1 expression 
levels were correlated with a better response (62). Conversely, mutations in TP53, NF1 or 
CREBBP were associated with a negative response (63).
The same authors also reported the results from another portion of the aforemen-
tioned phase II clinical trial, comparing low dose cytarabine (LDAC) with or without glas-
degib in AML and MDS patients under randomized conditions (26). In this section of the 
BRIGHT AML 1003 trial (NCT01546038), LDAC was administered subcutaneously for 10 
days per 28-day cycles, as monotherapy for 41 patients and associated with 100 mg glas-
degib administered orally every day of the cycle for 84 patients (Fig. 2). In each group, over 
half of the patients were aged > 75 years. After the follow-up period (21.7 months and 20.1 
months on average for glasdegib/LDAC arm and LDAC arm, respectively), the median (80 
% CI) OS was 8.8 (6.9–9.9) months with combination therapy and 4.9 (3.5–6.0) months with 
LDAC alone. This significant OS improvement is reflected in a 49 % reduction in the risk 
of death for patients treated with glasdegib/LDAC, compared to LDAC alone. These data 
have been refined by treatment-response and exposure-response analyses, also specifying 
that variability in glasdegib exposures did not impact the risk of death (64). CR was 
achieved in 17 % (n = 15) and 2.3 % (n = 1) patients in glasdegib/LDAC arm and LDAC arm, 
respectively. Noteworthy, the CR rate in the LDAC arm was quite lower than previously 
reported in other trials (65–67), with no evident reason. The median time to CR among 
patients receiving the combination therapy was 1.9 months, with a 9.9-month median dura-
tion of CR. In the MDS group, patients treated with combination therapy (n = 10) achieved 
a 22.8 % reduction in the risk of death relative to LDAC alone (n = 6), which was considered 
as an encouraging result despite the small sample size. The addition of glasdegib to LDAC 
was generally well tolerated, with a manageable safety profile even in elderly patients. 
Nevertheless, 9 out of 10 and 3 out of 6 patients permanently discontinued study treat-
ments due to TRAEs in combination therapy arm and LDAC arm, respectively.
Fig. 2. Design and main results of the randomized, placebo-controlled section of the phase 2 BRIGHT 
AML 1003 study.
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This first randomized phase II study highlighted the combination of glasdegib with 
LDAC as a compelling therapeutic approach, especially for AML patients ineligible for IC 
(68). Long-term outcomes in the same patients (43.4 months and 42.0 months follow-up 
period on average for glasdegib/LDAC arm and LDAC arm, respectively) confirmed the 
previous results (median OS = 8.3 vs. 4.3 months) (69). A post-hoc analysis also showed that 
the addition of glasdegib to LDAC vs. LDAC alone was associated with improved OS both 
in patients with de novo AML and secondary AML (70). Overall, although other combina-
tion therapies like HMA with venetoclax have been associated with much higher response 
rates in AML (71), the clinical efficacy and good safety profile of the glasdegib/LDAC com-
bination assessed in this study were pivotal evidence for glasdegib regulatory approval 
(72). Late follow-up analyses remained consistent with the primary findings (73). In 2020, 
Cortes et al. published a post-hoc analysis suggesting possible clinical benefits of glasdegib 
in the absence of CR (74), as the addition of glasdegib to the LDAC tend to improve OS 
versus LDAC alone (median OS = 5.0 and 4.1, respectively) in patients who did not achieve 
CR. Moreover, durable recovery of the absolute neutrophil count, hemoglobin and platelets 
was observed in more patients receiving combination therapy, though improved OS could 
not be obviously correlated to the reach of a specific blood count threshold (75).
Tremblay et al. reused the data of the previous study and have resorted to indirect or 
simulated treatment comparison methods to compare the effectiveness of glasdegib + 
LDAC association with HMAs in AML (76). Published clinical trials evaluating AZA or 
decitabine vs. LDAC in elderly AML patients ineligible for IC were used to obtain  comparative 
data. Despite the risk of imperfect adjustment depending on the model applied, this 
 indirect comparison compensates for the absence of direct, head-to-head trial results. 
Based on this methodology, glasdegib associated with LDAC tended to demonstrate 
 consistently favored OS hazard ratios (HR) over either AZA or decitabine (HR = 0.424; 
95 % CI = 0.228–0.789 and HR = 0.505; 95 % CI = 0.269–0.949, respectively). A second study 
performed an indirect treatment comparison between glasdegib + LDAC and AZA 
 depending on bone marrow blasts count (77). Both unadjusted HRs and HRs corrected for 
the potential imbalances at baseline between the trials suggested that glasdegib + LDAC 
association may be preferred over AZA, regardless of bone marrow blasts count, in previ-
ously untreated, chemotherapy-ineligible AML patients.
Glasdegib was also evaluated in a single-center, open-label phase II study 
(NCT01842646) as a monotherapy (100 mg daily oral dose during 28 days, up to 4 cycles) in 
35 patients (median age = 73 years) with MDS, CMML or AML (74, 15 and 11 %, respec-
tively) who have experienced refractory disease, progression or relapse following prior 
HMA therapy (78, 79). Although the treatment was safe and well-tolerated, only 6 % of 
patients (n = 2) achieved an objective response. Nineteen patients had stable disease (me-
dian OS = 20.6 months), however, the limited activity of glasdegib as a single agent sup-
ports its greater interest in combination therapy, as previously stated (80).
Finally, Kent et al. conducted a dual-center phase II study evaluating the ability of 
glasdegib to prevent post-allogeneic stem cell transplantation (ASCT) relapse in 31 AML 
and MDS patients at high risk for this outcome (81). Patients received 100 mg oral glasdegib 
daily for 28-day cycles, starting from day 28 to 100 post-ASCT and continuing for 1 year in 
the absence of relapse or intolerance. The median time on treatment before permanent 
discontinuation was 142 days (range, 28–336 days). More than 90 % of patients (n = 28) experi-
enced at least 1 AE attributable to glasdegib and half of the patients (n = 16)  experienced 
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at least 1 grade ≥ 2 AE. Two-thirds of patients (n = 19) had glasdegib interruptions because 
of AEs and 5 had dose reductions, mostly because of cramping or myalgia. The significant 
quality-of-life issues objectified in this study and caused by glasdegib, possibly due in part 
to interactions with the multiple concomitant medications routinely administered post- 
-ASCT, suggested a probable risk of poor compliance with treatment. Overall, among these 
31 patients, 1- and 2-year OS rates were 64.5 and 46.8 %, respectively. Relapse-free survival 
rates were 41.9 and 31.5 %, respectively. Eight patients had a measurable residual disease 
relapse at a median time of 180.5 days post-ASCT and 17 patients experienced a morpho-
logical relapse at a median time of 333 days post-ASTC. This pilot study, although not 
randomized, suggested limited ability for glasdegib to prevent relapse in a high-risk post- 
-ASCT setting and highlighted a non-optimal tolerance profile that could affect both 
 adherence and quality of life.
Phase III
The BRIGHT AML 1019 trials (NCT03416179) were designed as two independent, 
phase III, randomized (1:1), double-blind studies evaluating the efficacy of oral glasdegib 
100 mg once daily or placebo plus one or two standard chemotherapy regimens in adults 
with untreated AML (Fig. 3) (82, 83). In the intensive study (n = 200:200), patients received 
glasdegib or placebo for up to two years or until disease progression, treatment failure, 
hematological relapse, toxicity, elimination of measurable/minimal residual disease, 
 patient refusal or death. Glasdegib was combined with cytarabine and daunorubicin (‘7 + 3’ 
induction therapy followed by 1 to 4 28-day cycles of consolidation therapy with cytara-
bine alone). In the nonintensive study (n = 160:160), patients received glasdegib or placebo 
plus AZA given subcutaneously or intravenously for 7 days in 28-day cycles, for at least 6 
cycles or until disease progression, toxicity, patient refusal or death. Assignment to the 
intensive or nonintensive study was decided by the investigator.
In each study, eligible patients could receive allogeneic stem cell transplantation and 
may continue glasdegib or placebo up to 2 years after randomization. The results of this 
Fig. 3. Design of the randomized, placebo-controlled phase 3 BRIGHT AML 1019 study.
18
C. Fersing and F. Mathias: Update on glasdegib in acute myeloid leukemia – broadening horizons of Hedgehog pathway inhibitors, Acta 


































































































































































































































































































































































































































































































































































































































































































































































































































































































C. Fersing and F. Mathias: Update on glasdegib in acute myeloid leukemia – broadening horizons of Hedgehog pathway inhibitors, Acta 
Pharm. 72 (2022) 9–34.
 
study, when available, may support the expansion of the current registration of glasdegib 
to include treatment of AML patients in combination with cytarabine plus daunorubicine 
or AZA, in addition to its already approved indication. A summary of the main results 
obtained from clinical trials with glasdegib is given in Table II.
Pharmacokinetics and drugs interactions
Using samples collected from initial phase I and II studies (35, 36, 51), Lin et al. develo-
ped a PK model to characterize glasdegib kinetic behavior in patients and to predict the 
sources of variability in its PK parameters (84, 85). Data from 269 patients with various 
haematological or solid tumor malignancies (median age and weight was 69 years and 
78.6 kg; median creatinine renal clearance was 80.9 mL min–1; normal hepatic function in 
81 % patients) showed that glasdegib followed a two-compartment first-order absorption 
model. Age, sex, race and hepatic function were not found to be significant covariates on 
glasdegib PK parameters, unlike the baseline percentage of bone marrow blasts, creatinine 
renal clearance and use of CYP3A4 inhibitors. However, these variation factors were not 
considered to alter glasdegib PK in a clinically meaningful way at the recommended 
100 mg daily dose.
Initial clinical trials did not measure oral bioavailability of glasdegib, thus, Shaik et al. 
ran an open-labeled, phase I, randomized, 2-sequence, 2-treatment, 2-period, crossover 
study in healthy volunteers under fasting conditions to quantify this parameter 
(NCT03270878, 86). Drug plasma concentrations were monitored by HPLC-MS in 12 sub-
jects who received either 100 mg p.o. or 50 mg i.v. glasdegib. After a washout period of 6 
days or more, the subjects received the treatment they did not get during the first period. 
The absolute oral bioavailability of glasdegib was 77.12 % and other PK parameters values 
were comparable to those measured in the previous phase I  trials (Tmax = 1.52 h; Vd = 199.6 
L; T1/2 = 14.3 h). The same authors also showed, through two other phase I open-label stud-
ies on healthy subjects, that neither the formulation (small- or large-particle size tablets 
and oral solution), nor the food intake, nor the coadministration of an acid-reducing agent 
(rabeprazole) had a clinically meaningful impact on oral bioavailability and pharmaco-
kinetics of glasdegib (87, 88).
Other PK parameters of glasdegib were studied by Lam et al. in a single-dose, open- 
-label phase I  clinical trial (NCT02110342), through the administration of 14C-glasdegib 
(100 mg oral dose containing ~ 3,7 kBq) in 6 healthy volunteers (89). The mean Tmax in 
plasma was measured at 0.75 h post-administration and the mean T1/2 of total radioactivity 
was 14.2 h, slightly shorter than previously stated (50). Hepatic metabolism, with particu-
lar involvement of CYP3A4, was confirmed as the main clearance pathway of glasdegib, 
primarily forming hydroxy, N-desmethyl and N-glucuronide primary metabolites. These 
components represented < 10 % of circulating radioactivity in plasma. Renal and faecal 
routes tended to contribute almost equally to glasdegib elimination (49 and 42 % of the 
administered dose, respectively).
Effects of strong CYP3A4 inhibitors on the metabolism of glasdegib were studied in 
depth by Shaik et al. in a crossover protocol (NCT01749085) where healthy volunteers rece-
ived a single oral administration of 200 mg glasdegib, in either a fasted or fed state, spaced 
by an 8-day washout. Subsequently, subjects received 400 mg ketoconazole by oral route 
once daily for 7 days and 200 mg glasdegib on day 4 (90). Administration of glasdegib 
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concomitantly with a high-fat, high-calorie meal caused a 13 % lower AUC0-inf and 34 % 
lower Cmax compared with glasdegib alone. On the contrary, administration of glasdegib 
in the presence of ketoconazole resulted in a 140 % higher AUC0-inf and 40 % higher Cmax 
compared with glasdegib alone. Whereas the influence of food was not considered clini-
cally meaningful, caution should be used in the case of concomitant administration of 
strong CYP3A4 inhibitors with glasdegib (91).
The influence of strong CYP3A4 inducers was also explored by the same team in an 
open-label, fixed sequence, two-period phase I  study (NCT02430545, 92). On period 1 (5 
days), 12 healthy volunteers received 100 mg oral glasdegib on day 1. On period 2 (12 days), 
subjects were administered 600 mg oral rifampicin from day –6 to day 4 and 100 mg glas-
degib on day 1 (washout was 11 days between the 2 doses of glasdegib). With rifampicin, 
a 29.6 % and 64.7 % reduction was observed in AUC0-inf and Cmax of glasdegib, respectively. 
Mean half-life decreased from 13.4 h to 5.1 h and apparent oral clearance increased from 
12.3 to 41.4 L h–1. Thus, the association between glasdegib and CYP3A4 inducers should be 
avoided. If concomitant use can’t be avoided, the dose of glasdegib can be doubled and 
then readjusted 7 days after the inducer is stopped (91).
A summary of clinical trials investigating the pharmacokinetics of glasdegib is pro-
vided in Table III.
Safety
The most commonly observed adverse effects of glasdegib in clinical trials were he-
matologic disorders (anaemia, febrile neutropenia, thrombocythemia), nausea, decreased 
appetite, fatigue, muscle spasms, diarrhea and pneumonia (47, 50, 51). Most of these AEs 
appeared to be exposure-dependent (93). In the randomized arm of the BRIGHT AML 1003 
study (26), grade 3–4 AEs occurred in 64.3 and 56.1 % of patients in the glasdegib + LDAC 
group and in the LDAC group, respectively. Much rarer events were also observed, such 
as abnormal Frederica’s QTc (in both groups), serious acute kidney injury, serious muscle 
spasm or elevation of liver enzymes (in combination therapy group). Grade 5 AEs were 
reported in 28.6 and 41.5 % of patients in these groups, respectively. AEs leading to a dose 
reduction or temporary treatment interruption were reported in 26.2 and 56.0 % of patients 
in the glasdegib + LDAC group and in 0 and 31.7 % of patients in the LDAC group. The 
proportions of serious AEs were relatively similar between the two treatment groups (78.6 % 
with combination therapy and 78 % with LDAC alone), moreover, permanent treatment 
discontinuation were less frequent in glasdegib + LDAC group than in LDAC group (35.7 
and 46.3 %, respectively). Although glasdegib was associated with significant toxicities, 
most adverse events were managed with dose interruption or dose modification. In routine 
clinical practice, a dose modification should be considered in case of G2 muscle-related AE, 
haematologic toxicity, G3 nonhaematologic AEs or QT interval prolongation (91). In a brief 
report, Tavares et al. highlighted significant toxicities of glasdegib plus LDAC in compas-
sionate use in 6 high-risk and heavily pretreated AML patients (94). Although this observa-
tion was made in a small number of patients, it could suggest a poorer tolerance of this 
treatment protocol in the salvage setting than in previously untreated patients.
Concerning the influence of glasdegib on QTc interval, Masters et al. led a phase I 
study (NCT03162900) on 36 healthy volunteers who received a single dose of 150 or 300 mg 
glasdegib, 400 mg moxifloxacin (positive control) and placebo, according to 4 different 
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administration sequences (95, 96). None of the subjects reached Frederica’s formula cor-
rected QTc (QTcF) interval value ≥ 480 s or an increased baseline in QTcF interval ≥ 30 ms 
after the administration of any treatment (mean differences in QTcF between glasdegib 
and placebo systematically < 20 ms). Thus, although glasdegib had an effect on cardiac 
repolarization, it was below the 20 ms threshold of clinical significance usually set in an 
oncology context (97, 98).
Based on its mechanism of action, like other HH pathway inhibitors (99, 100), glas-
degib could cause foetal harm and severe birth defects when administered to pregnant 
women, although there are no clinical data on its impact in this patients population. Its use 
in women of childbearing potential should therefore be concomitant with an effective 
contraceptive solution, continued for at least 30 days after the last administration. In males, 
glasdegib may be present in semen, which can be a source of exposure for female partners 
with reproductive potential. Because it binds significantly to plasma proteins, the fraction 
of glasdegib found in milk during breastfeeding is likely to be low; however, no clinical 
data are available for confirmation (101). In view of the potential adverse effects in breast-
fed children, breastfeeding is not recommended during treatment with glasdegib and for 
at least one week after the last dose.
Dosing, administration and counseling points
Glasdegib is available under the brand-name DAURISMO as oral 25 mg or 100 mg 
film-coated tablets that may be taken with or without food. Only one tablet should be 
taken for the recommended dose of 100 mg daily in combination with LDAC (51), whereas 
the administration of two 25 mg tablets should be considered in case of dosage reduction 
based on safety and tolerability. A missed dose can be made up unless more than 10 h have 
passed since the scheduled administration time. Patients should be encouraged to adhere 
to a roughly consistent administration schedule each day.
Pharmacists are the leading healthcare professionals in counseling patients about 
their treatment with glasdegib as they can help prevent and guide the management of AEs 
associated with this therapy. Concerning the management of common non-haematologic 
AEs, patients should receive proper counseling on the use of supporting care medications 
or nonpharmacologic management strategies adapted to the SMOi therapeutic class (102–
104). The early identification of non-haematologic grade 3 AEs could allow the rapid inter-
ruption of treatment until the symptoms diminish or disappear (91). A review of con-
comitant treatments with glasdegib could also be important to limit the risk of drug-drug 
interactions, especially with inducers or inhibitors of CYP3A4, QT-prolonging agents or 
P-glycoprotein substrates (90–92).
Place in therapy
Although it can occur in patients of any age, AML is mainly a disease of older adults 
(105). Privileged care for patients with newly diagnosed AML consist of an intensive 
 induction chemotherapy strategy, however, a large proportion of patients is not eligible for 
these treatments (106). As well as AZA and decitabine, the combination of glasdegib with 
LDAC is now one of the therapeutic alternatives in older patients and those ineligible for 
IC (107), particularly because of its notable effectiveness on overall survival compared to 
23
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LDAC alone (26, 73). In recent years, FDA also approved several new targeted therapies 
such as gemtuzumab ozogamicin, venetoclax, ivosidenib or midostaurin to treat patients 
with newly diagnosed AML (108). In this very shifting landscape, the selection of patients 
best suited for these treatments is an essential questioning. Cortes et al. published expert 
recommendations suggesting that glasdegib in combination with LDAC could effectively 
be considered for patients aged ≥ 75, with poorer risk profiles and prognostic scores, ineli-
gible for IC, with secondary AML or who received prior HMA for MDS (109). Patients with 
hepatic or renal impairment (110, 111) and severe cardiac disease could also benefit from 
this combination therapy. Despite a monthly list price of 16,925 USD for glasdegib, the 
budget impact of including glasdegib plus LDAC as first-line treatment from a US health 
plan perspective was estimated to be low for the US payers, as the eligible patient popula-
tion size remains small (112).
CONCLUSIONS
Glasdegib is a recent targeted anticancer agent for the management of AML, particu-
larly in elderly patients not eligible for IC. In combination with LDAC, the use of glasdegib 
almost doubled the median overall survival compared to LDAC alone in phase II clinical 
trials that led to the FDA approval of glasdegib (113). Definitive results of the BRIGHT 
AML 1019 phase III clinical trial, when available, will provide new information on the risk/
benefit profile of glasdegib and on its place in the AML therapeutic strategy in combina-
tion with cytotoxic agents such as cytarabine plus daunorubicin (which remain the refer-
ence IC regimen for AML patients). Its oral administration route as well as its manageable 
safety profile could allow better medication adherence and quality of life, especially if a 
therapeutic education of patients on common AEs is set up. Going forward, several clinical 
trials involving glasdegib are currently underway (Table IV), investigating its use as 
monotherapy or in combination with other anticancer agents in both haematological 
(NCT04231851, NCT04168502, NCT04051996 (114), NCT04655391, NCT04093505, 
NCT03390296) and solid cancers (NCT03466450).
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